Biggest Study Yet Backs GlaxoSmithKline (Jobs) Cervical Cancer Shot
Published: Jun 28, 2007
LONDON (Reuters) - GlaxoSmithKline Plc's experimental vaccine Cervarix has proved more than 90 percent effective in preventing precancerous lesions due to two types of a virus responsible for most cases of cervical cancer. Interim results from the biggest cervical cancer vaccine trial to date, published on Thursday in the Lancet medical journal, confirm previous promising data. Cervarix is a rival to Merck & Co. Inc.'s similar product Gardasil.